Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Arthritis, Rheumatoid × ISIS104838 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Methotrexate 3 olokizumab 2 veltuzumab 1 upadacitinib 1 tocilizumab 1 mavrilimumab 1 golimumab 1 andecaliximab 1 Vaccines 1 Tumor Necrosis Factor Inhibitors 1 Saline Solution 1 RC-18 1 Interleukin 1 Receptor Antagonist Protein 1 ISIS104838 1 Herpes Zoster Vaccine 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00048321 2022-12-05

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Ionis Pharmaceuticals, Inc.

Phase 2 Completed

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡